
    
      This will be a single-dose, open-label, two-period replicate pilot study with orally
      administered chlorpromazine hydrochloride 25 mg (sugar coated tablets) conducted under
      fasting conditions in at least 16 healthy male and female subjects at a single study center.

      Up to 20 eligible subjects will be enrolled in the study with 16 evaluable subjects to
      complete the study.

      Analytes to be measured will be Chlorpromazine and 7-hydroxy-Chlorpromazine (free) as
      stipulated by FDA Guidance for assessment of bioequivalence for Chlorpromazine.
    
  